



Advances in Salivary Gland Carcinoma

Guest Editors:

Dr. Giulio Cantù

Former Director Head and Neck Surgery Department, Fondazione IRCCS Istituto dei Tumori, Milan, Italy

Prof. Dr. Laura D. Locati

1. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
2. Translational Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy

Prof. Dr. Luiz P. Kowalski

Department of Head and Neck Surgery, University of Sao Paulo Medical School, Sao Paulo 05403-000, Brazil

Deadline for manuscript submissions:

31 August 2024

Message from the Guest Editors

Dear Colleagues,

Salivary gland malignancies represent one of the most complex groups of tumors from a pathological point of view. They show a striking range of morphological diversity between different tumor types. In fact, all the WHO classifications that have occurred over time report more than 20 histotypes. Furthermore, the rarity of some of these histotypes needs a skilled pathologist for diagnosis. Parotid tumors are far more common than neoplasms in the other sites (70–80%), but only 20% are malignant. Approximately 50% of the tumors in the submandibular gland and 70% of those in the minor salivary glands are malignant. Because of the high frequency of parotid tumors, despite the low rate of malignant ones, parotid malignancies are more common than those of other salivary glands.

These and other topics related to salivary gland carcinomas will be covered in this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)